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Background
Study and direct comparison of HIV-1 Env specific anti-
body responses elicited by HIV vaccines can provide use-
ful information to identify vaccine candidates in early
stage trials with greater potential of providing a protective
immune response. With the goal of describing qualitative
differences in humoral responses elicited by disparate HIV
vaccine delivery approaches, we evaluated serum samples
from three independent trials: HVTN 041, a recombinant
protein based vaccine; HVTN 203, a combination canary-
pox prime plus protein boost vaccine, and DP6-001, a
DNA prime plus protein boost vaccine.
Methods
Humoral responses elicited by each vaccine trial were
evaluated by ELISA for endpoint binding titer against a
heterologous clade B antigen JR-FL and evaluated for anti-
body specificity using overlapping linear peptides and
mAbs in a pseudoviral based competitive binding assay.
Neutralizing specificity was evaluated against model clade
B isolates in a pseudoviral system.
Results
We determined that binding titers are not indicative of the
domain specificities or neutralizing activities of the sera
being generated through immunization. Analysis of anti-
body specificity indicated that all three trials elicited high
titers of antibodies targeted to the V3 loop and co-receptor
binding site of the HIV envelope. However, antibodies tar-
geted to the CD4 binding domain were elicited signifi-
cantly more frequently and in higher titer in individuals
from the DP6-001 trial. Additionally, the presence of
these CD4 binding site specific antibodies correlated with
increased neutralization breadth against model clade B
isolates.
Conclusion
In summary, this study confirmed in human volunteers
that a DNA prime-protein boost regimen is highly capable
of eliciting antibodies responses against key epitopes on
HIV-1 Env. *HVTN041 and HVTN203 sera were kindly
provided by HVTN Ancillary Study Group
from AIDS Vaccine 2009
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